Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Barry E Greene. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Barry E Greene har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:SAGE / Sage Therapeutics, Inc. | President and CEO, Director | 0 |
US:KPTI / Karyopharm Therapeutics Inc. | Director | 13 606 |
US:ACOR / Acorda Therapeutics, Inc. | Director | 10 000 |
US:ALNY / Alnylam Pharmaceuticals, Inc. | President | 0 |
US:RGLS / Regulus Therapeutics Inc. | Director, 10% Owner | 25 000 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Barry E Greene. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp KPTI / Karyopharm Therapeutics Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i KPTI / Karyopharm Therapeutics Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2015-04-02 | KPTI | Greene Barry E | 3 000 | 29,3128 | 200 | 439,6920 | 87 938 | 14 | 34.8300 | −80 972 | −92,08 |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i KPTI / Karyopharm Therapeutics Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Barry E Greene som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-07-31 |
|
4 | SAGE |
Sage Therapeutics, Inc.
Common Stock |
D - Sale to Issuer | −53 229 | 0 | −100,00 | ||||
2025-07-31 |
|
4 | SAGE |
Sage Therapeutics, Inc.
Common Stock |
U - Other | −46 940 | 0 | −100,00 | ||||
2025-04-11 |
|
4 | SAGE |
Sage Therapeutics, Inc.
Common Stock |
F - Taxes | −4 862 | 100 169 | −4,63 | 6,91 | −33 596 | 692 168 | |
2025-04-11 |
|
4 | SAGE |
Sage Therapeutics, Inc.
Common Stock |
A - Award | 19 964 | 105 031 | 23,47 | ||||
2024-08-07 |
|
4 | SAGE |
Sage Therapeutics, Inc.
Common Stock |
F - Taxes | −12 273 | 85 067 | −12,61 | 8,96 | −109 966 | 762 200 | |
2024-08-07 |
|
4 | SAGE |
Sage Therapeutics, Inc.
Common Stock |
A - Award | 50 400 | 97 340 | 107,37 | ||||
2022-11-15 |
|
4 | SAGE |
Sage Therapeutics, Inc.
Common Stock |
P - Purchase | 14 500 | 46 940 | 44,70 | 34,48 | 500 022 | 1 618 693 | |
2022-08-15 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Common Stock |
M - Exercise | 7 576 | 13 606 | 125,64 | 1,48 | 11 250 | 20 205 | |
2022-05-20 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Nonstatutory Stock Option (right to buy) |
A - Award | 23 900 | 23 900 | |||||
2022-02-15 |
|
4 | SAGE |
Sage Therapeutics, Inc.
Stock Option (Right to Buy) |
A - Award | 69 920 | 69 920 | |||||
2021-08-09 |
|
4 | SAGE |
Sage Therapeutics, Inc.
Common Stock |
P - Purchase | 23 640 | 32 440 | 268,64 | 43,15 | 1 020 054 | 1 399 770 | |
2021-06-17 |
|
4 | SAGE |
Sage Therapeutics, Inc.
Common Stock |
P - Purchase | 8 800 | 8 800 | 56,32 | 495 627 | 495 627 | ||
2021-06-04 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
A - Award | 10 000 | 10 000 | |||||
2021-05-21 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Nonstatutory Stock Option (right to buy) |
A - Award | 23 900 | 23 900 | |||||
2021-01-06 |
|
4 | SAGE |
Sage Therapeutics, Inc.
Stock Options (Right to buy) |
A - Award | 390 000 | 390 000 | |||||
2020-10-05 |
|
4 | SAGE |
Sage Therapeutics, Inc.
Stock Options (Right to buy) |
A - Award | 20 000 | 20 000 | |||||
2020-09-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −44 530 | 0 | −100,00 | |||
2020-09-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 346 | 70 343 | −4,54 | 124,38 | −416 175 | 8 749 262 |
2020-09-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −27 109 | 73 689 | −26,89 | 123,39 | −3 344 980 | 9 092 486 |
2020-09-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −14 075 | 100 798 | −12,25 | 122,66 | −1 726 440 | 12 363 883 |
2020-09-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 44 530 | 114 873 | 63,30 | 9,14 | 407 004 | 1 049 939 |
2020-09-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −3 176 | 0 | −100,00 | ||||
2020-09-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −155 | 3 176 | −4,65 | ||||
2020-09-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −155 | 3 176 | −4,65 | ||||
2020-09-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
G - Gift | 155 | 155 | |||||
2020-09-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
G - Gift | 3 176 | 65 412 | 5,10 | ||||
2020-08-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −1 036 | 46 589 | −2,18 | ||||
2020-08-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −1 124 | 38 876 | −2,81 | ||||
2020-08-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −1 587 | 88 413 | −1,76 | ||||
2020-08-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −1 184 | 23 816 | −4,74 | ||||
2020-08-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 184 | 67 167 | 1,79 | 42,22 | 49 988 | 2 835 791 | |
2020-08-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 124 | 65 983 | 1,73 | 88,95 | 99 980 | 5 869 188 | |
2020-08-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 036 | 64 859 | 1,62 | 96,45 | 99 922 | 6 255 651 | |
2020-08-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 587 | 63 823 | 2,55 | 63,00 | 99 981 | 4 020 849 | |
2020-07-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −22 265 | 44 530 | −33,33 | |||
2020-07-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −22 265 | 62 236 | −26,35 | 159,99 | −3 562 177 | 9 957 138 |
2020-07-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 22 265 | 84 501 | 35,78 | 9,14 | 203 502 | 772 339 |
2020-06-17 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
A - Award | 15 000 | 15 000 | |||||
2020-05-26 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Nonstatutory Stock Option (right to buy) |
A - Award | 16 400 | 16 400 | |||||
2020-05-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −22 265 | 66 795 | −25,00 | |||
2020-05-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −22 265 | 62 236 | −26,35 | 149,99 | −3 339 527 | 9 334 778 |
2020-05-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 22 265 | 84 501 | 35,78 | 9,14 | 203 502 | 772 339 |
2020-04-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −64 | 62 236 | −0,10 | 106,65 | −6 826 | 6 637 469 | |
2020-04-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −1 599 | 62 300 | −2,50 | 104,75 | −167 495 | 6 525 925 | |
2020-04-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 5 417 | 63 899 | 9,26 | ||||
2020-03-17 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Stock Option (right to buy) |
M - Exercise | −3 030 | 0 | −100,00 | ||||
2020-03-17 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Common Stock |
M - Exercise | 3 030 | 6 030 | 101,00 | 0,03 | 100 | 199 | |
2020-02-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 29 925 | 29 925 | |||||
2019-12-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy) |
A - Award | 9 999 | 19 998 | 100,00 | ||||
2019-11-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy) |
A - Award | 9 999 | 9 999 | |||||
2019-10-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | −5 544 | 3 486 | −61,40 | ||||
2019-10-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 5 544 | 58 482 | 10,47 | ||||
2019-10-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −58 913 | 0 | −100,00 | |||
2019-10-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −58 913 | 52 938 | −52,67 | 89,99 | −5 301 581 | 4 763 891 |
2019-10-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 58 913 | 111 851 | 111,29 | 16,43 | 967 941 | 1 837 712 |
2019-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 25 000 | 33,33 | ||||
2019-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 10 000 | 40 000 | 33,33 | 88,95 | 889 500 | 3 558 000 | |
2019-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 46 | 3 003 | 1,56 | ||||
2019-06-21 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
A - Award | 15 000 | 15 000 | |||||
2019-06-07 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Nonstatutory Stock Option (right to buy) |
A - Award | 25 000 | 25 000 | |||||
2019-06-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 18 750 | 50,00 | ||||
2019-06-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 52 | 2 957 | 1,79 | ||||
2019-06-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 21 | 2 905 | 0,73 | ||||
2019-03-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 32 500 | 32 500 | |||||
2018-09-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 12 500 | 100,00 | ||||
2018-09-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 10 000 | 30 000 | 50,00 | ||||
2018-08-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 10 000 | 20 000 | 100,00 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Based Stock Option 2014 (right to buy) |
A - Award | 15 875 | 47 625 | 50,00 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Based Stock Option 2013 (right to buy) |
A - Award | 15 000 | 45 000 | 50,00 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
G - Gift | 9 030 | 9 030 | |||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −9 030 | 52 938 | −14,57 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 29 | 2 884 | 1,02 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 28 | 2 855 | 0,99 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 17 | 2 827 | 0,60 | ||||
2018-06-29 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
A - Award | 15 000 | 15 000 | |||||
2018-06-20 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Nonstatutory Stock Option (right to buy) |
A - Award | 17 000 | 17 000 | |||||
2018-05-23 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
M - Exercise | −10 000 | 0 | −100,00 | ||||
2018-05-23 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Common Stock |
F - Taxes | −8 727 | 1 273 | −87,27 | 23,10 | −201 594 | 29 406 | |
2018-05-23 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Common Stock |
M - Exercise | 10 000 | 10 000 | 20,16 | 201 600 | 201 600 | ||
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 300 | 61 968 | −2,05 | 145,41 | −189 033 | 9 010 767 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 165 | 63 268 | −12,65 | 144,67 | −1 325 901 | 9 152 982 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 644 | 72 433 | −10,66 | 143,58 | −1 241 106 | 10 399 930 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 217 | 81 077 | −10,21 | 142,68 | −1 315 082 | 11 568 066 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −7 250 | 90 294 | −7,43 | 141,74 | −1 027 615 | 12 798 272 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 884 | 97 544 | −2,87 | 140,43 | −405 000 | 13 698 104 |
2018-03-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 30 000 | 30 000 | |||||
2017-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 6 250 | |||||
2017-11-08 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2017-10-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −85 316 | 0 | −100,00 | |||
2017-10-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −85 316 | 100 428 | −45,93 | 125,00 | −10 664 500 | 12 553 500 |
2017-10-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 85 316 | 185 744 | 84,95 | 21,35 | 1 821 497 | 3 965 634 |
2017-09-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −5 359 | 94 641 | −5,36 | ||||
2017-09-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −6 485 | 85 915 | −7,02 | ||||
2017-09-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 5 359 | 100 428 | 5,64 | 18,66 | 99 999 | 1 873 986 | |
2017-09-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 6 485 | 95 069 | 7,32 | 7,10 | 46 044 | 674 990 | |
2017-09-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −76 815 | 0 | −100,00 | |||
2017-09-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2013 (Right to Buy) |
A - Award | 15 000 | 15 000 | |||||
2017-09-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −76 815 | 88 584 | −46,44 | 100,00 | −7 681 500 | 8 858 400 |
2017-09-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 76 815 | 165 399 | 86,71 | 31,39 | 2 411 223 | 5 191 875 |
2017-08-03 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
M - Exercise | X | −10 000 | 0 | −100,00 | |||
2017-08-03 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Common Stock |
S - Sale | X | −10 000 | 0 | −100,00 | 21,57 | −215 697 | |
2017-08-03 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Common Stock |
M - Exercise | X | 10 000 | 10 000 | 18,21 | 182 100 | 182 100 | |
2017-07-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2014 (right to buy) |
A - Award | 15 875 | 31 750 | 100,00 | ||||
2017-06-16 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Nonstatutory Stock Option (right to buy) |
A - Award | 17 000 | 17 000 | |||||
2017-06-02 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
A - Award | 15 000 | 15 000 | |||||
2017-02-13 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
M - Exercise | X | −723 | 0 | −100,00 | |||
2017-02-13 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Common Stock |
S - Sale | X | −723 | 0 | −100,00 | 22,65 | −16 376 | |
2017-02-13 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Common Stock |
M - Exercise | X | 723 | 723 | 22,13 | 16 000 | 16 000 | |
2017-01-05 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
M - Exercise | X | −3 017 | 0 | −100,00 | |||
2017-01-05 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Common Stock |
S - Sale | X | −3 017 | 0 | −100,00 | 19,26 | −58 113 | |
2017-01-05 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Common Stock |
M - Exercise | X | 3 017 | 3 017 | 15,91 | 48 000 | 48 000 | |
2016-12-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 25 000 | 25 000 | |||||
2016-12-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −55 605 | 0 | −100,00 | |||
2016-12-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −500 | 88 584 | −0,56 | 44,07 | −22 036 | 3 904 074 |
2016-12-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −16 976 | 89 084 | −16,01 | 43,28 | −734 747 | 3 855 689 |
2016-12-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −14 349 | 106 060 | −11,92 | 42,61 | −611 345 | 4 518 729 |
2016-12-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 55 605 | 120 409 | 85,80 | 22,75 | 1 265 014 | 2 739 305 |
2016-06-17 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Nonstatutory Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2016-06-10 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
A - Award | 15 000 | 15 000 | |||||
2016-03-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −8 940 | 89 060 | −9,12 | ||||
2016-03-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −7 600 | 92 400 | −7,60 | ||||
2016-03-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 7 600 | 64 804 | 13,29 | 7,10 | 53 960 | 460 108 | |
2016-03-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 8 940 | 57 204 | 18,52 | 9,14 | 81 712 | 522 845 | |
2016-02-03 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2014 (right to buy) |
A - Award | 15 875 | 15 875 | |||||
2015-12-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 40 000 | 40 000 | |||||
2015-12-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −2 100 | 48 264 | −4,17 | ||||
2015-08-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −3 185 | 76 815 | −3,98 | ||||
2015-08-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −4 684 | 85 316 | −5,20 | ||||
2015-08-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −6 087 | 58 913 | −9,36 | ||||
2015-08-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −2 000 | 98 000 | −2,00 | ||||
2015-08-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −4 395 | 0 | −100,00 | ||||
2015-08-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −6 621 | 0 | −100,00 | ||||
2015-08-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 2 000 | 50 364 | 4,14 | 9,14 | 18 280 | 460 327 | |
2015-08-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 6 087 | 48 364 | 14,40 | 16,43 | 100 009 | 794 621 | |
2015-08-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 4 684 | 42 277 | 12,46 | 21,35 | 100 003 | 902 614 | |
2015-08-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 3 185 | 37 593 | 9,26 | 31,39 | 99 977 | 1 180 044 | |
2015-08-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 4 395 | 34 408 | 14,64 | 22,75 | 99 986 | 782 782 | |
2015-08-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 6 621 | 30 013 | 28,30 | 13,12 | 86 868 | 393 771 | |
2015-06-11 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
A - Award | 15 000 | 15 000 | |||||
2015-05-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −67 379 | 6 621 | −91,05 | |||
2015-05-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −67 379 | 23 392 | −74,23 | 125,00 | −8 422 375 | 2 924 000 |
2015-05-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 67 379 | 90 771 | 288,04 | 13,12 | 884 012 | 1 190 916 |
2015-05-26 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Nonstatutory Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2015-05-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
A - Award | 47 625 | 47 625 | |||||
2015-04-06 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Common Stock |
P - Purchase | 3 000 | 3 000 | 29,31 | 87 938 | 87 938 | ||
2014-12-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −1 000 | 74 000 | −1,33 | ||||
2014-12-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 000 | 23 392 | 4,47 | 13,12 | 13 120 | 306 903 | |
2014-12-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −11 200 | 22 392 | −33,34 | 100,00 | −1 120 000 | 2 239 200 |
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Based Stock Option (right to buy) |
A - Award | 15 000 | 15 000 | |||||
2014-11-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −33 200 | 0 | −100,00 | |||
2014-11-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −100 | 33 592 | −0,30 | 93,99 | −9 399 | 3 157 312 |
2014-11-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 462 | 33 692 | −13,95 | 90,96 | −496 818 | 3 064 591 |
2014-11-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 579 | 39 154 | −19,66 | 89,80 | −860 242 | 3 516 225 |
2014-11-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −18 059 | 48 733 | −27,04 | 89,11 | −1 609 321 | 4 342 822 |
2014-11-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 33 200 | 66 792 | 98,83 | 6,78 | 225 096 | 452 850 |
2014-11-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −11 100 | 33 200 | −25,06 | |||
2014-11-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −11 100 | 33 592 | −24,84 | 100,00 | −1 110 000 | 3 359 200 |
2014-11-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 11 100 | 44 692 | 33,04 | 6,78 | 75 258 | 303 012 |
2014-07-09 |
|
4 | KPTI |
Karyopharm Therapeutics Inc.
Nonstatutory Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2014-06-09 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
A - Award | 10 000 | 10 000 | |||||
2014-02-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −19 500 | 44 300 | −30,56 | ||||
2014-02-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −1 680 | 33 592 | −4,76 | 78,68 | −132 182 | 2 643 019 | |
2014-02-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 19 500 | 35 272 | 123,64 | 6,78 | 132 210 | 239 144 | |
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 90 000 | 90 000 | |||||
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −11 200 | 47 796 | −18,98 | ||||
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 11 200 | 15 772 | 244,97 | 6,78 | 75 936 | 106 934 | |
2013-10-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2013-06-03 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
A - Award | 10 000 | 10 000 | |||||
2013-05-30 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −14 928 | 0 | −100,00 | |||
2013-05-30 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −7 894 | 0 | −100,00 | |||
2013-05-30 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −14 928 | 4 572 | −76,55 | 30,00 | −447 840 | 137 160 |
2013-05-30 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 14 928 | 19 500 | 326,51 | 0,95 | 14 182 | 18 525 |
2013-05-30 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −7 894 | 4 572 | −63,32 | 30,00 | −236 820 | 137 160 |
2013-05-30 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 7 894 | 12 466 | 172,66 | 0,95 | 7 499 | 11 843 |
2013-03-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −24 058 | 0 | −100,00 | |||
2013-03-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −24 058 | 4 572 | −84,03 | 25,00 | −601 450 | 114 300 |
2013-03-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 24 058 | 28 630 | 526,20 | 0,95 | 22 855 | 27 198 |
2013-03-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −24 000 | 24 058 | −49,94 | |||
2013-03-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −24 000 | 4 572 | −84,00 | 24,43 | −586 270 | 111 684 |
2013-03-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 24 000 | 28 572 | 524,93 | 0,95 | 22 800 | 27 143 |
2012-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 100 000 | 100 000 | |||||
2012-11-07 |
|
4 | RGLS |
Regulus Therapeutics Inc.
Stock Option (Right to Buy) |
A - Award | 25 000 | 25 000 | |||||
2012-10-11 |
|
4 | RGLS |
Regulus Therapeutics Inc.
Series A Preferred Stock |
C - Conversion | −6 150 500 | 0 | −100,00 | ||||
2012-10-11 |
|
4 | RGLS |
Regulus Therapeutics Inc.
Common Stock |
C - Conversion | 6 150 500 | 6 150 500 | |||||
2012-06-07 |
|
4 | ACOR |
ACORDA THERAPEUTICS INC
Non-Employee Stock Option |
A - Award | 10 000 | 10 000 | |||||
2012-02-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 1 860 | 4 572 | 68,58 | 10,75 | 19 995 | 49 149 | |
2011-10-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | X | 742 | 742 | 6,73 | 4 996 | 4 996 | |
2007-01-10 | 3 | ACOR |
ACORDA THERAPEUTICS INC
No securities are beneficially owned. |
0 | ||||||||
2004-12-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 75 000 | 75 000 | |||||
2004-05-27 | 3 | ALNY |
ALNYLAM PHARMACEUTICALS INC
Common Stock |
52 631 |